Next Oncology

1. Merck Sharp & Dohme Corporation $4,364,106 152 payments
2. Mirati Therapeutics, Inc. $2,114,587 53 payments
3. AbbVie, Inc. $1,729,131 487 payments
4. E.R. Squibb & Sons, L.L.C. $1,366,454 16 payments
5. Astellas Pharma Inc $1,025,562 688 payments
6. Amgen Inc. $1,013,642 11 payments
7. BeiGene, Ltd. $791,266 65 payments
8. BeOne Medicines USA, Inc. $568,561 46 payments
9. Pfizer Inc. $554,042 27 payments
10. BeiGene USA, Inc. $375,734 41 payments

1. A Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-0482 as monotherapy and in combination with pembrolizumab in participants with advanced,metastatic solid tumors. $1,096,643 45 payments
2. A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation $1,025,562 688 payments
3. A Phase 1 Open-label Dose Escalation Study of BDB001 as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors $711,000 3 payments
4. AMG 193 Combo with IDE397 MAT2A $680,525 2 payments
5. A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies $561,268 1 payment
6. A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With MTAP Homozygous Deletion $494,014 3 payments
7. A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced $478,663 5 payments
8. A Phase 1 Open Label Crossover Study to Establish Bioequivalence Between the Proposed Soft Gel Talazoparib Capsule Formulation and the Current Talazoparib Commercial Formulation and to Estimate the Food Effect on Pharmacokinetics of the Proposed Talazoparib Soft Gel Capsule Formulation in Participants With Advanced Solid Tumors $461,567 6 payments
9. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab $456,762 188 payments
10. A Phase Ib ,II Study of Apg-115 In Combination With Pembrolizumab In Patients With Unresectable Or Metastatic Melanomas Or Advanced Solid Tumors $434,500 2 payments

1. Patient care $81,951 37 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.